z-logo
open-access-imgOpen Access
Low-Frequency Nevirapine (NVP)–Resistant HIV-1 Variants Are Not Associated With Failure of Antiretroviral Therapy in Women Without Prior Exposure to Single-Dose NVP
Author(s) -
Valerie F. Boltz,
Yajing Bao,
Shahin Lockman,
Elias K. Halvas,
Mary F. Kearney,
James McIntyre,
Robert T. Schooley,
Michael D. Hughes,
John M. Coffin,
John W. Mellors,
Beth Zwickl,
C. Kityo Mutuluuza,
Christine Kaseba,
Charles C. Maponga,
Heather Watts,
Daniel R. Kuritzkes,
Thomas Campbell,
Lynn Kidd-Freeman,
Monica Carten,
Jane Hitti,
Mary Marovich,
Peter Mugyenyi,
Sandra Rwambuya,
Ian Sanne,
Beverly Putnam,
Cheryl Marcus,
Carolyn Wester,
Robin DiFrancesco,
Annie Beddison,
Sandra Nusinoff Lehrman,
Francesca Aweeka,
Betty J. Dong,
Peter Ndhleni Ziba,
Michael S. Saag,
William C. Holmes,
Scott M. Hammer
Publication year - 2014
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jit635
Subject(s) - nevirapine , medicine , cart , tenofovir , human immunodeficiency virus (hiv) , antiretroviral therapy , virology , viral load , mechanical engineering , engineering
Low-frequency nevirapine (NVP)-resistant variants have been associated with virologic failure (VF) of initial NVP-based combination antiretroviral therapy (cART) in women with prior exposure to single-dose NVP (sdNVP). We investigated whether a similar association exists in women without prior sdNVP exposure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom